Ferritin Nanocage Enables Oral GLP-1 Delivery That Works Where Standard Injection Drug Fails | Research

The takeaway

GLP-1 peptide fused to ferritin nanocages survived stomach digestion and reduced blood glucose and food intake when given orally to diabetic mice — while oral exenatide alone had no effect.

Oral GLP-1 works via ferritin; alone it fails
The ferritin-GLP-1 fusion significantly reduced blood glucose and food intake when given orally to diabetic mice, while the same GLP-1 analog without ferritin showed zero effect

What the researchers found

Ferritin nanocages remained largely intact after 30 minutes of simulated gastric digestion and were highly resistant to intestinal proteolysis. In vivo, orally administered ferritin reached the intestinal tract without significant degradation. The GLP-1-ferritin fusion (HLG) was absorbed via TfR1-mediated endocytosis in Caco-2 monolayers. Oral HLG significantly reduced blood glucose levels and food intake in type 2 diabetic mice, while oral exenatide alone showed no such effects.

Why it matters

The holy grail of GLP-1 drug development is an effective oral formulation — avoiding the needles that many patients dislike. While oral semaglutide (Rybelsus) exists, it requires complex absorption enhancers and fasting. This ferritin-based approach offers a fundamentally different strategy: protect the peptide in a natural protein cage that the gut actively absorbs via existing receptor pathways. The complete failure of oral exenatide without the ferritin carrier dramatically demonstrates the technology's value.

How the study worked

Researchers engineered a fusion protein (HLG) linking GLP-1 to the C-terminus of heteropolymer ferritin. Gastrointestinal stability was tested through simulated digestion (gastric and intestinal). In vivo stability was confirmed by tracking orally administered ferritin in mice. Cellular absorption mechanisms were studied in Caco-2 intestinal cell monolayers. Efficacy was tested in type 2 diabetic mice, comparing oral HLG against oral exenatide.

What this study cannot tell us

This is a preclinical mouse study. The diabetic mouse model may not predict human oral bioavailability. The fusion protein manufacturing complexity and scale-up feasibility were not addressed. Long-term safety of repeated oral ferritin nanocage administration is unknown. Comparison was against free exenatide, not against the engineered oral semaglutide formulation that uses absorption enhancers. Dosing relative to injectable GLP-1 drugs was not quantified.

How to read the evidence

This is a preclinical proof-of-concept study with comprehensive in vitro characterization and in vivo validation in diabetic mice. The technology is rigorously demonstrated but at an early stage — human translation is uncertain.

When this study was published

Published in 2026, this study represents cutting-edge peptide delivery technology that addresses one of the most commercially important challenges in drug development — making injectable peptide drugs work as pills.

The bigger picture

Oral delivery of peptide drugs is arguably the most important challenge in peptide therapeutics. Ferritin nanocages offer a unique solution because they're naturally occurring proteins that the body already has mechanisms to absorb (via transferrin receptors). Unlike synthetic nanoparticles, ferritin is biocompatible and non-immunogenic. This platform could potentially deliver not just GLP-1 but any therapeutic peptide that currently requires injection — insulin, parathyroid hormone, calcitonin — potentially transforming chronic disease management for millions of patients.

Questions still open

How does the oral bioavailability of ferritin-delivered GLP-1 compare to oral semaglutide (Rybelsus)?
Could this ferritin platform deliver other peptide drugs (insulin, PTH) that currently require injection?
Would repeated oral dosing of ferritin nanocages trigger immune responses or affect iron metabolism?

Common questions

Why can't GLP-1 drugs like Ozempic be taken as pills?

GLP-1 peptides are destroyed by stomach acid and digestive enzymes within minutes. The one oral GLP-1 drug available (Rybelsus/oral semaglutide) uses a special absorption enhancer and requires fasting — and still has much lower bioavailability than injection. This study uses a different approach: packaging GLP-1 inside ferritin protein cages that naturally resist digestion and are actively absorbed by the gut.

What is ferritin and why is it good for drug delivery?

Ferritin is a naturally occurring protein in the body that stores iron inside a hollow cage-like structure. This cage is remarkably stable — it resists stomach acid and digestive enzymes. Gut cells have specific receptors (TfR1) that actively transport ferritin from the intestine into the body. By attaching GLP-1 to ferritin, researchers created a delivery system that exploits this natural absorption pathway to get the peptide drug past the gut barrier intact.

Read the original research

Heteropolymer ferritin nanocages as delivery vehicles for oral delivery of GLP-1 peptides.

Journal of colloid and interface science, 703(Pt 1), 139092

View on PubMed ↗Publisher’s paper ↗

Citation

Qian, Yiran; Chang, Xiaoxi; Sun, Mingyang; Chen, Yunqi; Zang, Jiachen; Lv, Chenyan; Zhao, Guanghua; Zhang, Tuo. (2026). Heteropolymer ferritin nanocages as delivery vehicles for oral delivery of GLP-1 peptides.. Journal of colloid and interface science, 703(Pt 1), 139092. https://doi.org/10.1016/j.jcis.2025.139092